Efficacy and safety of lorcaserin in obese adults: a meta‐analysis of 1‐year randomized controlled trials (RCTs) and narrative review on short‐termRCTs
- 21 January 2013
- journal article
- research article
- Published by Wiley in Obesity Reviews
- Vol. 14 (5) , 383-392
Abstract
Summary: Lorcaserin is a new anti‐obesity drug recently approved byUSFood and Drug Administration. We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) to evaluate the association of lorcaserin therapy with weight loss and adverse events in obese adults (18–65 years old). Weight loss of 3.23 kg (95% confidence interval [CI]: 2.70, 3.75) and body mass index reduction of 1.16 kg m−2(95%CI: 0.98, 1.34) was observed compared with placebo inRCTsof 1 year duration. The use of lorcaserin for 8 and 12 weeks reduced weight of 1.60 kg (95%CI: 0.34, 2.86) and 2.9 kg (95%CI: 2.2, 3.5), respectively. In comparison to placebo, lorcaserin decreased waist circumference, blood pressure, total cholesterol, low‐density lipoprotein‐cholesterol and triglycerides, however did not statistically affect heart rate or high‐density lipoprotein‐cholesterol. Headache, nausea and dizziness were found to be significantly higher in the patients receiving lorcaserin than patients receiving placebo, whereas diarrhoea is no more likely than in patients receiving placebo. In conclusion, lorcaserin achieves modest weight loss and appears to be well tolerated. Clinical and pharmacovigilance studies with longer study duration are needed to inform of the long‐term efficacy and safety of lorcaserin.Keywords
This publication has 29 references indexed in Scilit:
- Transtheoretical model for dietary and physical exercise modification in weight loss management for overweight and obese adults2011
- Digging deeper into obesityJournal of Clinical Investigation, 2011
- Lorcaserin, A 5-HT2CReceptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy ExpenditureThe Journal of Clinical Endocrinology & Metabolism, 2011
- The use of serotonergic drugs to treat obesity – is there any hope?Drug Design, Development and Therapy, 2011
- Lorcaserin—not a new weapon in the battle with appetiteNature Reviews Endocrinology, 2010
- Long‐term changes in blood pressure following orlistat and sibutramine treatment: a meta‐analysisObesity Reviews, 2009
- 5-HT2CRs Expressed by Pro-Opiomelanocortin Neurons Regulate Energy HomeostasisNeuron, 2008
- Serotonin 5-HT2C Receptor Agonist Promotes Hypophagia via Downstream Activation of Melanocortin 4 ReceptorsEndocrinology, 2007
- ObesityThe Lancet, 2005
- Psychological interventions for overweight or obesity2005